Table 1.
Baseline Characteristics of Patients with Lymphocyte Counts Above and Below 500 at 2 Months
| All Patients (N = 53) | Patients with Lymphocyte Counts 500 at 2 Months (N = 29) | Patients with Lymphocyte Counts < 500 at 2 Months (N = 24) | p value* | |
|---|---|---|---|---|
| Demographics | ||||
| Age: median (range) | 64 (47–84) | 63 (47–81) | 62 (47–84) | .86 |
| Age 65 years: # (%) | 23 (43) | 13 (45) | 10 (42) | .82 |
| Male: # (%) | 29 (55) | 19 (66) | 10 (42) | .08 |
| Caucasian: # (%) | 45 (85) | 26 (90) | 19 (79) | .29 |
| ECOG performance score = 0: # (%) | 33 (62) | 19 (66) | 14 (58) | .59 |
| Baseline laboratory data | ||||
| Total lymphocyte count: median (range) | 1945 (580–4200) | 2030 (580–3280) | 1599 (870–4200) | .57 |
| Lymphocyte ≥ 1,000: # (%) | 48 (91) | 26 (90) | 22 (92) | .80 |
| AST: median (range) | 28 (12–70) | 28 (12–53) | 28 (12–70) | .42 |
| BUN: median (range) | 12 (5–34) | 14 (5–34) | 12 (5–27) | .31 |
| CA19-9: median (range) | 41 (0.1–400) | 29 (0.1–440) | 60 (4.9–203) | .39 |
| Albumin: median (range) | 4 (2.8–5.1) | 4.1 (2.8–4.7) | 3.9 (3–5.1) | .56 |
| Alk phos: median (range) | 113 (54–493) | 103 (54–493) | 129 (59–492) | .18 |
| Tumor staging data | ||||
| Tumor location: No. head (%) | 43 (81) | 22 (76) | 21 (88) | .54 |
| Tumor size: median centimeters (range) | 3 (1.4–9.5) | 3.5 (1.4–9.5) | 3 (1.5–6) | .69 |
| Poorly differentiated pathology: #(%) | 23 (43) | 11 (40) | 12 (50) | .38 |
| Positive margins: # (%) | 25 (47) | 13 (45) | 12 (50) | .71 |
| Positive nodes: # (%) | 48 (92) | 27 (93) | 21 (91) | .81 |
| Whipple procedure: # (%) | 44 (83) | 23 (79) | 21 (88) | 0.43 |
| Postoperative treatment data | ||||
| Radiation dose: median cGy (range) | 5040 (2700–5760) | 5040 (2750–5580) | 5000 (2700–5760) | .25 |
| 5-fU based chemotherapy: # % | 31 (59) | 16 (55) | 15 (63) | .59 |